Abzu accelerates the development of new, innovative drugs with our proprietary explainable AI and expertise in RNA therapeutics.
We’re redefining the potential of RNA therapeutics through our specialized workflow with ASOs, siRNAs, and antimiRs.
This focus ensures our therapeutics have high activity and exhibit minimal off-target effects, heralding a new era of precision medicine.
Whether we start with designs or your data, Abzu provides you the insights and confidence to accelerate your R&D and transform RNA Tx concepts into market-ready drugs.
Contrary to the data-heavy demands of black-box AI, our technology thrives on minimal data. This efficiency not only accelerates the discovery process, but also reduces your barrier to entry to develop new, innovative drugs.
This benchmark from a real client case predicting molecule toxicity (using the same number of model features) is a testament to our proven team, technology, and results.
Let’s have a conversation about your targets, therapies, and goals. If you share our vision for unlocking the future of RNA Tx with explainable AI, then please complete the form below to start the conversation.
Co-funded by the
European Union.
© 2024 Abzu Aps. All rights reserved. Abzu®, QLattice®, and Feyn® are registered trademarks.
CVR DK39248530
CIF B67165647